More from Clinical Trials
Paying €90m upfront for rights to generalized pustular psoriasis drug.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.
Lynkuet will compete with Astellas's Veozah/Veoza
More from R&D
Learn more about the challenges faced by today’s drug developers and the critical factors to consider as sponsors navigate the supply chain, keep up with regulatory requirements, and ensure patient access. Discover more about the role of generics and how Aspire Pharma can help.
Insights from Novotech on Evolving Trends Impacting Global Clinical Development
Join Andrew Warmington, Manufacturing Editor at Citeline, in conversation with Tom Hickey, Director of Therapeutic Strategy at Novotech, a global full-service clinical CRO dedicated to accelerating the development of advanced and novel therapeutics.
Insights from Novotech on Evolving Trends Impacting Global Clinical Development